Brief: E.F. Hutton Advises On Strategic Merger Between Apimeds And Mindwave
17/12/2025 13:27
Dec 17 (Reuters) - Apimeds Pharmaceuticals US Inc APUS.A: E.F. HUTTON ADVISES ON STRATEGIC MERGER BETWEEN APIMEDS AND MINDWAVE, ALIGNING BIOTECH GROWTH WITH AI-ENABLED FINANCIAL INNOVATION Source text: ID:nGNX7dNQJc Further company coverage: APUS.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apimeds Pharmaceuticals US
See all newsBrief: Apimeds Pharmaceuticals Us Inc Vin Menon Continues To Serve As The Company’S Chief Executive Officer
Brief: Apimeds Pharmaceuticals Appoints Youngjik Cho As Chairman Of Board
Brief: Apimeds Pharmaceuticals Us Inc. Announces Material Breach Of Merger Agreement By Inscobee Inc And Apimeds Inc
Brief: E.F. Hutton Advises On Strategic Merger Between Apimeds And Mindwave
Brief: Apimeds And Mindwave Announce Merger, Integrating Biotech Growth With AI